Recombinant Human ACTR2 Protein, N-His

Introduction to Recombinant Human ACTR2 Protein

Recombinant proteins are proteins that are produced through genetic engineering techniques, allowing for the production of large quantities of specific proteins. These proteins have a wide range of applications in biotechnology, medicine, and research. One such protein is Recombinant Human ACTR2 Protein, which has gained significant attention in recent years due to its unique structure, activity, and potential applications.

Structure of Recombinant Human ACTR2 Protein

Recombinant Human ACTR2 Protein, also known as Activin Receptor Type 2, is a transmembrane protein that belongs to the transforming growth factor-beta (TGF-β) superfamily. It is composed of 509 amino acids and has a molecular weight of approximately 56 kDa. The protein consists of a signal peptide, an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain contains a ligand-binding region, while the intracellular domain has a serine/threonine kinase activity.

Activity of Recombinant Human ACTR2 Protein

The primary function of Recombinant Human ACTR2 Protein is to act as a receptor for the TGF-β superfamily ligands, including activins, inhibins, and bone morphogenetic proteins (BMPs). Upon ligand binding, the extracellular domain of ACTR2 interacts with the ligand, leading to the activation of the intracellular kinase domain. This, in turn, triggers a signaling cascade that regulates various cellular processes such as cell proliferation, differentiation, and apoptosis.

In addition to its role as a receptor, Recombinant Human ACTR2 Protein also has a crucial role in embryonic development. It is involved in the formation of the mesoderm and the establishment of the left-right axis during early embryogenesis. Furthermore, ACTR2 has been implicated in the regulation of cell migration and adhesion, making it a potential therapeutic target for cancer treatment.

Applications of Recombinant Human ACTR2 Protein

Recombinant Human ACTR2 Protein has a wide range of potential applications in biotechnology, medicine, and research. One of the most significant applications of this protein is in the development of therapeutic agents for various diseases. ACTR2 has been shown to play a crucial role in the development and progression of several types of cancer, making it a potential target for cancer treatment. Inhibitors of ACTR2 have been developed and are currently being tested in clinical trials for the treatment of various cancers, including breast, lung, and prostate cancer.

Moreover, Recombinant Human ACTR2 Protein has also been used in the development of tissue engineering scaffolds for regenerative medicine. The ability of ACTR2 to regulate cell proliferation and differentiation makes it a promising candidate for the development of biomaterials that can promote tissue regeneration. Additionally, ACTR2 has been shown to play a role in bone formation, making it a potential target for the treatment of bone diseases such as osteoporosis.

In research, Recombinant Human ACTR2 Protein is used as a tool to study the TGF-β signaling pathway. The availability of large quantities of this protein allows for its use in various biochemical and cellular assays to understand the mechanisms of TGF-β signaling and its role in various cellular processes.

Conclusion

Recombinant Human ACTR2 Protein is a crucial member of the TGF-β superfamily, with a unique structure and diverse functions. Its role as a receptor for TGF-β ligands and its involvement in various cellular processes make it a promising target for therapeutic interventions. The availability of large quantities of this protein through recombinant technology has opened up new avenues for its use in biotechnology, medicine, and research. With ongoing research and clinical trials, the potential applications of Recombinant Human ACTR2 Protein are likely to expand, making it an essential protein in the field of biotechnology.

ProteoGenix catalogue number ARO-P11861. For research use only.

Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 46.92 kDa; Fragment: Met1-Arg394; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet